| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 7909-IL-010/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 1399-IL-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56541SS | |||
| Azide and BSA Free | NBP2-33223 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 8134-IL-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 1258-IL-025/CF | |||
MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." alt="PC‑3 human prostate cancer cell line was stained with Human IL‑17E/IL‑25 Monoclonal Antibody (Catalog # MAB1258, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." class="big_thumb" />
1399-IL) was serially diluted and captured by Rat Anti-Mouse IL‑17E/IL‑25 Monoclonal Antibody (Catalog # MAB13991) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse IL‑17E/IL‑25 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1399) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" alt="Recombinant Mouse IL‑17E/IL‑25 (Catalog # 1399-IL) was serially diluted and captured by Rat Anti-Mouse IL‑17E/IL‑25 Monoclonal Antibody (Catalog # MAB13991) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse IL‑17E/IL‑25 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1399) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1399-SP | |||
MAB0061, open histogram), followed by Phycoerythrin-conjugated Anti-Rat IgG F(ab')2Secondary Antibody (Catalog # F0105B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." alt="Tramp‑C1 mouse prostate cancer cell line was stained with Mouse IL‑17E/IL‑25 Monoclonal Antibody (Catalog # MAB13991, filled histogram) or isotype control antibody (Catalog # MAB0061, open histogram), followed by Phycoerythrin-conjugated Anti-Rat IgG F(ab')2Secondary Antibody (Catalog # F0105B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB1399-SP | |||
| Carrier Free | MAB1399-500 | |||
1399-IL) induces CXCL1/GROa secretion in the the HT-29 human colon adenocarcinoma cell line in a dose-dependent manner (orange line), as measured by Human CXCL1/GROa DuoSet (Catalog # DY275). CXCL1/GROa Secretion elicited by Recombinant Mouse IL-17E/IL-25 (10 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse IL-17E/IL-25 Monoclonal Antibody (Catalog # MAB13992). The ND50 is typically 0.005-0.025 µg/mL." alt="Recombinant Mouse IL-17E/IL-25 (Catalog # 1399-IL) induces CXCL1/GROa secretion in the the HT-29 human colon adenocarcinoma cell line in a dose-dependent manner (orange line), as measured by Human CXCL1/GROa DuoSet (Catalog # DY275). CXCL1/GROa Secretion elicited by Recombinant Mouse IL-17E/IL-25 (10 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse IL-17E/IL-25 Monoclonal Antibody (Catalog # MAB13992). The ND50 is typically 0.005-0.025 µg/mL." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB13992-SP | |||
DY275). Under these conditions, CXCL1/GRO alpha secretion elicited by IL-17E/IL-25 is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-17E/IL-25 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1258). The ND50 is typically 0.04-0.24 ug/mL." alt="Recombinant Human IL-17E/ IL-25 induces CXCL1/GRO alpha secretion in HT-29 human colon adenocarcinoma cell line in a dose-dependent manner (orange line), as measured by the Human CXCL1/GRO alpha Duoset (Catalog # DY275). Under these conditions, CXCL1/GRO alpha secretion elicited by IL-17E/IL-25 is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-17E/IL-25 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1258). The ND50 is typically 0.04-0.24 ug/mL." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1258-SP | |||
![Western Blot: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Analysis of IL-17E using IL-17E monoclonal antibody. Mouse testis lysate probed with IL-17E antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-68C1039-2-Western-Blot-NB100-56541-img0007.jpg "Western Blot: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Analysis of IL-17E using IL-17E monoclonal antibody. Mouse testis lysate probed with IL-17E antibody at 2 ug/mL.")
![Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Tissue section of mouse liver using IL17E/IL25 antibody clone 68C1039.2 at 1:150. The antibody generated a diffused cytoplasmic staining in the hepatocytes with a very strong signal in the sinusoidal endothelial cells.](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-68C1039-2-Immunohistochemistry-Paraffin-NB100-56541-img0004.jpg)
![Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Tissue section of mouse kidney using IL17E/IL25 antibody clone 68C1039.2 at 1:150. The antibody generated a diffused cytoplasmic staining in the tubular and ductal epithelia cells, and a strong positivity in the inter-tubular/ductal blood vessels.](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-68C1039-2-Immunohistochemistry-Paraffin-NB100-56541-img0005.jpg)
![Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Adrenal cortex, Human](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-68C1039-2-Immunohistochemistry-NB100-56541-img0006.jpg)
![Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-310202415525274.jpg)
![Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-31020241612663.jpg)
![Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-310202415532053.jpg)
![Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - Overexpression of IL25 was found in CRC patients & predicts a poor prognosis. (A) Immunohistochemistry (IHC) staining of IL25 was performed in a tissue microarray consisting of 74 CRC tumor tissues & adjacent colon tissues (left). Statistical analysis of IL25 staining in adjacent specimens & CRC specimens (right). (B) Protein levels of IL25 were detected by Western blotting in normal intestinal cells (CCD841) & CRC cell lines (left). The right panel showed the quantitative analysis of the gray scan. The ImageJ software was used for gray scanning. (C) Representative images of IL25 IHC staining at different clinical stages (up). Correlation between IL25 expression & various clinical stages (down). (D) Overall survival curves of 49 CRC patients in correlation with intra-tumor IL25 IHC-scores. High IL25 expression was considered IHC-Score >6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-3102024168219.jpg)
![Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-3102024165736.jpg)
![Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - Overexpression of IL25 was found in CRC patients & predicts a poor prognosis. (A) Immunohistochemistry (IHC) staining of IL25 was performed in a tissue microarray consisting of 74 CRC tumor tissues & adjacent colon tissues (left). Statistical analysis of IL25 staining in adjacent specimens & CRC specimens (right). (B) Protein levels of IL25 were detected by Western blotting in normal intestinal cells (CCD841) & CRC cell lines (left). The right panel showed the quantitative analysis of the gray scan. The ImageJ software was used for gray scanning. (C) Representative images of IL25 IHC staining at different clinical stages (up). Correlation between IL25 expression & various clinical stages (down). (D) Overall survival curves of 49 CRC patients in correlation with intra-tumor IL25 IHC-scores. High IL25 expression was considered IHC-Score >6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-31020241682197.jpg)
![Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-310202415533830.jpg)
![Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - Overexpression of IL25 was found in CRC patients & predicts a poor prognosis. (A) Immunohistochemistry (IHC) staining of IL25 was performed in a tissue microarray consisting of 74 CRC tumor tissues & adjacent colon tissues (left). Statistical analysis of IL25 staining in adjacent specimens & CRC specimens (right). (B) Protein levels of IL25 were detected by Western blotting in normal intestinal cells (CCD841) & CRC cell lines (left). The right panel showed the quantitative analysis of the gray scan. The ImageJ software was used for gray scanning. (C) Representative images of IL25 IHC staining at different clinical stages (up). Correlation between IL25 expression & various clinical stages (down). (D) Overall survival curves of 49 CRC patients in correlation with intra-tumor IL25 IHC-scores. High IL25 expression was considered IHC-Score >6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-310202415533813.jpg)
![Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-310202415535127.jpg)
![Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-310202415535171.jpg)
![N/A IL-17E/IL-25 [Biotin]](http://images.novusbio.com/fullsize/elisa/DATA_IL17E_DY1399_ELISA_1641.jpg "N/A IL-17E/IL-25 [Biotin]")
1399-IL) was serially diluted and captured by Rat Anti-Mouse IL‑17E/IL‑25 Monoclonal Antibody (Catalog # MAB13991) coated on a Clear Polystyrene Microplate (Catalog # 
